Congressional Budget Office maps out how current rebating practices may change in Medicare Part D under the drug pricing provisions of the Inflation Reduction Act.
Price discounts conceded to Medicare Part D through negotiation will replace some manufacturer rebates currently provided to plans, leading to a $27bn decline in such rebates in 2031, the Congressional Budget Office projects in a recently-released report.
CBO estimates that net prices for selected drugs will decrease by roughly 50%, on average, as a result of the Medicare price negotiation program established by the Inflation Reduction Act....
The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.
In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.
The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.
